-
Price Momentum
LLY is trading near the top of its 52-week range and above its 200-day simple moving average.
-
Price change
The price of LLY shares has increased $0.49 since the market last closed. This is a 0.04% rise.
-
Last closed at $1.15K.
The stock has since dropped $6.58 in pre-market trading.
Key terms
About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
-
Market cap: $1085.32B
A market capitalization above $200 billion places LLY in the mega-capitalization category.
Key terms
Ad Feedback
Smart score
Latest LLY news
Today
6:40am ET
Novo Stock (NVO) Is Falling in Pre-Market Today, September 21 — Here’s Why
Today
4:16am ET
Eli Lilly & Co (LLY) Receives a Buy from Barclays
Yesterday
10:55am ET
Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports
Sep 19, 2026
9:10am ET
Lilly, Novo face lawsuits over GLP-1 vision loss risk, WSJ says
Sep 19, 2026
5:01am ET
Echostar, Enbridge, Rivian, Samsara, Eli Lilly Trending
Sep 18, 2026
2:00pm ET
Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers
Sep 18, 2026
12:31pm ET
Lilly’s New FORAY: Vepugratinib Targets FGFR3-Driven Bladder Cancer
Sep 18, 2026
10:40am ET
U.S. weighs allowing most pharma licensing deals with China, Reuters says
Sep 18, 2026
8:30am ET
Entera Receives $9 Price Target and New ‘Outperform’ Rating From Leerink Partners (NASDAQ: ENTX)
Sep 18, 2026
7:30am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)
Sep 18, 2026
7:20am ET
Eli Lilly price target raised to $1,284 from $1,273 at Guggenheim
Sep 17, 2026
9:55am ET
Psychedelic: Definium’s LSD-based drug meets endpoints in GAD study
Sep 17, 2026
6:00am ET
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and Eli Lilly & Co (LLY)
Sep 16, 2026
10:34am ET
Novo (NVO) Partners with Anthropic on AI Drug Discoveries
Sep 16, 2026
9:55am ET
Ginkgo Bioworks announces partnership with Lilly TuneLab
Sep 16, 2026
8:16am ET
Twist Bioscience enters agreement with Lilly TuneLab
Sep 16, 2026
4:08am ET
3 Healthcare Stocks with More Than 20% Upside and Recent Buy Ratings
Sep 15, 2026
12:01pm ET
Midday Fly By: Stocks see further pressure from higher bond yields
Sep 15, 2026
10:45am ET
Eli Lilly Stock (LLY) Gets New Buy Rating as Weight-Loss Drug Sales Accelerate
Sep 15, 2026
9:41am ET
Ulta Beauty, Etsy upgraded: Wall Street’s top analyst calls
Sep 15, 2026
9:11am ET
Video: Futures point to further declines as oil prices, Treasury yields climb
Sep 15, 2026
8:55am ET
Morning Movers: Vera Therapeutics surges after reporting IgAN study data
Sep 15, 2026
8:20am ET
Novo Nordisk Stock (NVO) Is Falling Despite Rebrand to ‘Novo’ — Here’s Why
Sep 15, 2026
4:35am ET
Eli Lilly upgraded to Buy from Hold at Berenberg
Sep 14, 2026
9:45pm ET
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Sep 14, 2026
3:02pm ET
Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup
Sep 14, 2026
12:30pm ET
Lilly Refines Abemaciclib Delivery in New Phase 1 Study, Supporting Long-Term Oncology Strategy
Sep 14, 2026
9:46am ET
SCHD vs. VIG: Which Dividend ETF Has the Edge in 2026?
Sep 14, 2026
7:00am ET
Healthcare Costs Are Rising Twice as Fast as Everything Else: Inside Milliman’s Healthcare Inflation ETFs (MHIG, MHIP)
Sep 11, 2026
12:30pm ET
Lilly’s Tirzepatide Targets Kidney Risk: What This Completed Trial Means for LLY Investors
Sep 11, 2026
10:55am ET
Eli Lilly Stock (LLY) in Focus as Company Completes AtaiBeckley Purchase
Nov 01, 2020
10:23am ET
ELI LILLY INVESTOR NOTICE
Oct 29, 2020
8:33pm ET
Eli Lilly Investor Alert
Oct 21, 2020
12:24pm ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm
Oct 19, 2020
9:15pm ET
Eli Lilly Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm
Oct 18, 2020
10:08am ET
Eli Lilly Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm
Oct 16, 2020
3:02pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm
Oct 15, 2020
8:12pm ET
Eli Lilly Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm
Oct 14, 2020
7:43pm ET
Eli Lilly Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm
LLY Financials
-
Total revenue: $65.18B (1Y), $22.97B (Q2)
Total Revenue increased 44.7% since last year and increased 16.04% since last quarter.
-
Net income: $20.64B (1Y), $7.09B (Q2)
Net Income increased 94.9% since last year and decreased 4.07% since last quarter.
-
Earnings per share: $22.95 (1Y), $7.94 (Q2)
EPS increased 95.93% since last year and decreased 3.83% since last quarter.
Key terms
Ad Feedback
LLY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LLY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
-
How competitors are chosen
LLY's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $1085.32B
A market capitalization above $200 billion places LLY in the mega-capitalization category.
